查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999372

基因合成市場：按產品、技術、應用和最終用戶分類－2026-2032年全球市場預測

Gene Synthesis Market by Product, Technology, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因合成市值將達到 51.9 億美元，到 2026 年將成長至 57.6 億美元，到 2032 年將達到 109.4 億美元，複合年成長率為 11.22%。

主要市場統計數據
基準年 2025 51.9億美元
預計年份：2026年 57.6億美元
預測年份 2032 109.4億美元
複合年成長率 (%) 11.22%

為下一代基因合成開發基礎設施，並為高階主管制定策略重點，轉化為競爭優勢。

基因合成領域正處於快速技術創新、不斷擴大的應用需求以及對通量和精度日益成長的期望的交匯點。自動化、酵素法和高保真組裝技術的最新進展降低了實驗室和服務供應商的進入門檻，同時也提高了設備、試劑和服務交付的性能標準。在此背景下，企業管理者不僅需要了解正在湧現的技術能力，還需要了解這些能力如何轉化為營運效率、法規遵循和合作夥伴選擇標準。

自動化、酵素技術創新以及一體化商業化模式的融合如何重塑基因合成領域的能力和競爭地位。

近年來，隨著自動化和酵素技術的創新從實驗室驗證走向實際應用平台，我們見證了變革性的轉變。這些轉變從根本上改變了各機構對通量、可重複性和單次反應成本的考量。自動化已不再局限於液體處理，而是擴展到整合序列設計、合成、組裝和品管的端到端工作流程，從而縮短了週期時間，並支援更多迭代實驗。

預測關稅措施對基因合成生態系統內的採購、供應鏈韌性和合作研發策略的連鎖影響。

美國2025年實施的關稅措施立即對基因合成工作流程中使用的儀器、試劑和特殊耗材的全球供應鏈產生了波動。採購團隊迅速採取行動，審查與供應商的契約，加快雙源採購策略的實施，並重新評估庫存政策，以應對關稅帶來的成本波動。同時，一些供應商調整了產品系列和分銷策略，透過本地生產和區域庫存中心來減輕關稅的影響。

整合細分洞察，揭示產品、技術、應用和最終用戶方面的差異如何驅動產品藍圖和競爭差異化。

市場細分為整個基因合成生態系統中投資和產品開發的優先排序提供了觀點，透過深入了解產品、技術、應用和最終用戶的各個層面，揭示了價值的創造所在。基於產品，市場被分為三大類：「儀器」、「試劑和耗材」以及「服務」。 「儀器」進一步細分為「自動化克隆設備」、「DNA合成儀」、「微陣列平台」和「聚合酵素連鎖反應熱迴圈儀」。 「試劑與耗材」進一步細分為緩衝液及其他耗材、酵素和試劑盒以及寡核苷酸。 「服務」則進一步細分為基礎基因合成、密碼子最佳化、基因克隆、基因文庫建構和誘變服務。這種層級結構凸顯了儀器製造商在可靠性、處理能力和整合度方面的競爭；試劑供應商在配方穩定性、批間一致性和監管文件方面競爭；而服務供應商透過智慧財產權保護、交貨時間和設計專業知識來脫穎而出。

影響美洲、歐洲、中東和非洲以及亞太地區採用、監管和區域供應趨勢的區域戰略挑戰。

區域趨勢對整個基因合成價值鏈的採用模式、監管預期和夥伴關係結構都有顯著影響。在美洲，對本土製造和轉化研究能力的投資持續推動先進設備和整合服務的快速應用。該地區在臨床應用監管方面往往領先領先地位，這反過來又促進了高通量合成解決方案的商業化，以及供應商與主要製藥合作夥伴之間的密切合作。

競爭行為、夥伴關係模式和產品策略區分了市場領導，並影響它們在基因合成生態系統中的長期定位。

基因合成生態系統中的主要企業如今不再僅依靠單一產品特性來競爭，而是透過技術深度、生態系統夥伴關係和服務可靠性的綜合優勢來取勝。投資於整合設計、合成和品管的模組化平台的公司，正日益受到尋求承包工作流程的客戶的青睞。同樣，能夠提供完善的技術文件和長期穩定性數據的試劑供應商，正在降低受監管終端用戶的准入門檻，並逐漸成為臨床和工業領域的首選。

為基因合成領域的領導企業提供實際的策略措施，以加速商業化、增強韌性，並將創新轉化為永續的競爭優勢。

產業領導者應優先考慮一系列切實可行的步驟，以平衡創新效率、供應鏈韌性和以客戶為中心的商業化。首先，投資於模組化自動化和檢驗的工作流程，以減少交接環節並加快可重複結果的實現，因為營運的一致性是研究可重複性和臨床應用的基礎。其次，建構穩健的供應商多元化策略和本地化支援體系，以降低關稅和物流風險，同時確保酵素、寡核苷酸和特殊耗材的穩定供應。

一種透明的調查方法，描述了用於深入了解基因合成的主要和次要資訊、檢驗過程和分析框架。

本分析採用結構化的調查方法，整合一手與二手訊息，強調資訊來源三角驗證、專家檢驗以及高度透明的分析架構。一手資訊包括與熟悉分子生物學、自動化工程、品質保證和商業領域領導的專家進行的結構化訪談和研討會。透過這些努力，我們得出了關於技術權衡、產品整合模式和終端用戶購買行為的解讀。

整合策略意義與未來展望，探討相關人員如何因應轉型並利用基因合成的進步。

綜上所述，這些洞見揭示了基因合成領域的格局：整合的工作流程、穩健的供應鏈以及應用主導的檢驗將決定哪些公司能夠將科學創新轉化為商業性價值。化學、酵素法和PCR等技術方法各具優勢，因此，企業需要明確策略方向，確定工程研發和產品上市時間的重點。同時，基礎設施、法規環境和採購慣例的區域差異，也要求企業制定在地化的實施方案，而非採用一刀切的方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因合成市場：依產品分類

  • 裝置
    • 自動克隆設備
    • DNA合成器
    • 微陣列平台
    • 聚合酵素連鎖反應熱迴圈儀
  • 試劑和耗材
    • 緩衝劑和其他消耗品
    • 酵素試劑盒
    • 寡核苷酸
  • 服務
    • 基礎基因合成
    • 基因複製
    • 突變引入服務

第9章 基因合成市場：依技術分類

  • 化學合成
    • H-膦酸酯合成
    • 亞磷醯胺合成
  • 酵素合成
    • 吉布森組裝
    • 金門集會
    • 連接酶鍊式反應
  • 基於PCR的合成

第10章 基因合成市場：依應用領域分類

  • 抗體和疫苗生產
  • 工業生物技術
  • 分子診斷
  • 幹細胞和細胞株工程
  • 合成生物學

第11章 基因合成市場：依最終用戶分類

  • 學術和研究機構
  • 臨床診斷檢查室
  • 合約研究機構
  • 製藥和生物技術公司

第12章 基因合成市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因合成市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因合成市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因合成市場

第16章：中國基因合成市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ansa Biotechnologies Inc.
  • Arbor Biotechnologies, Inc.
  • ATUM, Inc.
  • Azenta Life Sciences, Inc.
  • Bio Basic Inc.
  • Bioneer Corporation
  • DNA Script SA
  • Eurofins Scientific SE
  • Evonetix Ltd.
  • GenScript Biotech Corporation
  • Integrated DNA Technologies, Inc.
  • Merck KGaA
  • OriGene Technologies, Inc.
  • ProteoGenix SAS
  • Synbio Technologies Inc.
  • Telesis Bio, Inc.
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-3A2E844FEB5F

The Gene Synthesis Market was valued at USD 5.19 billion in 2025 and is projected to grow to USD 5.76 billion in 2026, with a CAGR of 11.22%, reaching USD 10.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.19 billion
Estimated Year [2026] USD 5.76 billion
Forecast Year [2032] USD 10.94 billion
CAGR (%) 11.22%

Setting the stage for next-generation gene synthesis and the strategic imperatives that executives must prioritize to convert capability into competitive advantage

The gene synthesis landscape sits at the intersection of rapid technological innovation, expanding application demand, and increasing expectations for throughput and accuracy. Recent advances in automation, enzymatic methods, and high-fidelity assembly techniques have lowered barriers to entry for laboratories and service providers alike, while simultaneously raising the performance baseline for instruments, reagents, and service offerings. In this context, executives must understand not only which capabilities are emerging but also how those capabilities translate into operational efficiencies, regulatory compliance, and partner selection criteria.

As organizations prioritize scalable workflows, they are re-evaluating procurement and R&D priorities to emphasize integrated solutions that shorten design-to-product cycles. The convergence of digital design tools with physical synthesis workflows has created new vectors for competitive differentiation, making cross-disciplinary collaboration between molecular biologists, automation engineers, and data scientists a core competency. Consequently, leaders should view gene synthesis not merely as a tactical procurement category but as a strategic capability that underpins product pipelines, diagnostic platforms, and synthetic biology initiatives.

How converging automation, enzymatic innovations, and integrated commercialization models are reshaping capabilities and competitive positioning across gene synthesis

The past several years have seen transformative shifts as automation and enzymatic innovations matured from laboratory proofs to deployable platforms. These shifts have fundamentally altered how organizations approach throughput, reproducibility, and cost per reaction. Automation has extended beyond liquid handling to incorporate end-to-end workflows that integrate sequence design, synthesis, assembly, and quality control, thereby compressing cycle times and enabling more iterative experimentation.

Simultaneously, enzymatic synthesis routes and refined PCR-based assembly methods have introduced alternatives to traditional chemical synthesis that reduce hazardous waste and improve scalability for longer constructs. These technical shifts are accompanied by changes in commercialization models: integrated instrument-plus-reagent offerings, expanded as-a-service capabilities for complex constructs, and deeper partnerships between platform providers and end users. Regulatory considerations and responsible innovation frameworks have also gained prominence, prompting providers to bake compliance-ready features into hardware and software. Taken together, these developments are shifting competitive advantage toward organizations that can deliver integrated, validated, and user-friendly workflows that meet both scientific and operational expectations.

Anticipating the cascading effects of tariff measures on procurement, supply chain resilience, and collaborative R&D strategies within gene synthesis ecosystems

United States tariff actions introduced in 2025 created immediate ripples across global supply chains for instruments, reagents, and specialty consumables used in gene synthesis workflows. Procurement teams responded by reviewing supplier contracts, accelerating dual-sourcing strategies, and re-evaluating inventory policies to buffer against duty-related cost volatility. In parallel, some vendors revised product portfolios and distribution strategies to mitigate tariff impacts through localized production or regionalized inventory hubs.

Beyond procurement, the tariff environment influenced R&D planning and collaboration models. Organizations with cross-border collaborations adjusted timelines and material flows to avoid disruption, while others accelerated investment in domestic manufacturing capabilities to reduce exposure. These adjustments often required closer alignment between commercial, legal, and technical teams to assess compliance, adapt pricing structures, and manage expectations for lead times.

Over time, stakeholders shifted toward a more granular view of supply chain risk that included tariff exposure as part of a broader resilience framework encompassing single-sourcing risk, logistical constraints, and regulatory complexity. This integrated approach to supply chain governance has become a strategic differentiator for companies that must balance innovation velocity with predictable access to instruments, enzymes, oligonucleotides, and specialized services. Consequently, resilience planning now integrates tariff scenarios as part of capital equipment decisions, long-term procurement strategies, and partnership selection.

Integrated segmentation insights revealing how product, technology, application, and end-user distinctions drive product roadmaps and competitive differentiation

Segmentation provides a lens for prioritizing investment and product development across the gene synthesis ecosystem, and nuanced understanding of product, technology, application, and end-user tiers reveals where value accrues. Based on Product, market is studied across Instruments, Reagents & Consumables, and Services. The Instruments is further studied across Automated Cloning Instruments, DNA Synthesizers, Microarray Platforms, and Thermal Cyclers. The Reagents & Consumables is further studied across Buffers & Other Consumables, Enzymes & Kits, and Oligonucleotides. The Services is further studied across Basic Gene Synthesis, Codon Optimization, Gene Cloning, Gene Library Construction, and Mutagenesis Services. This layering highlights that instrument manufacturers compete on reliability, throughput, and integration, whereas reagents providers compete on formulation stability, lot-to-lot consistency, and regulatory documentation, and service providers differentiate through IP protection, turnaround times, and design expertise.

Based on Technology, market is studied across Chemical Synthesis, Enzymatic Synthesis, and PCR Based Synthesis. The Chemical Synthesis is further studied across H-Phosphonate Synthesis and Phosphoramidite Synthesis. The Enzymatic Synthesis is further studied across Gibson Assembly, Golden Gate Assembly, and Ligase Chain Reaction. The PCR Based Synthesis is further studied across Assembly PCR, Ligase Chain Reaction, and Overlap Extension PCR. This technology taxonomy clarifies where technical trade-offs emerge: chemical routes offer mature, high-fidelity oligonucleotide production, enzymatic methods promise greener and scalable assembly for larger constructs, and PCR-based approaches remain essential for bespoke construct fabrication and iterative design cycles.

Based on Application, market is studied across Antibody & Vaccine Production, Industrial Biotechnology, Molecular Diagnostics, Stem Cell & Cell Line Engineering, and Synthetic Biology. Application-driven priorities shape performance requirements, such that vaccine development emphasizes speed and regulatory traceability, diagnostics emphasize reproducibility and sensitivity, and synthetic biology emphasizes modularity and scalability. Based on End-User, market is studied across Academic & Research Institutes, Clinical Diagnostics Laboratories, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies. Each end-user category imposes distinct purchasing rationales and support expectations: academic labs prioritize flexibility and cost-effectiveness, clinical labs prioritize accreditation and validation, CROs prioritize throughput and service reliability, and commercial biotech firms prioritize long-term supplier partnerships and integrated solutions.

Taken together, these segmentation layers inform commercialization strategies. Leaders that align product roadmaps and service models to the specific technical and operational priorities of target end users capture higher adoption and deeper partnerships. Moreover, cross-segmentation thinking - for example, mapping enzymatic synthesis advantages to synthetic biology and CRO workflows - clarifies where to invest in validation, training, and co-development to accelerate uptake.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape adoption, regulation, and localized supply dynamics

Regional dynamics exert a strong influence on adoption patterns, regulatory expectations, and the structure of partnerships across the gene synthesis value chain. In the Americas, investment in domestic manufacturing and translational research capabilities continues to support rapid adoption of advanced instruments and integrated service offerings. This region often leads in regulatory clarity for clinical applications, which in turn encourages commercialization of high-throughput synthesis solutions and close coordination between vendors and large pharmaceutical partners.

In Europe, Middle East & Africa, the ecosystem reflects a mosaic of strong research hubs, varying regulatory approaches, and increasing emphasis on collaborative consortia that pool capacity for complex synthetic biology projects. Policy debates around biosecurity and responsible innovation have been particularly active here, prompting vendors to invest in transparency, auditability, and compliance-enabling features for their platforms. These investments facilitate cross-border collaborations while meeting heightened governance expectations.

Across Asia-Pacific, infrastructure expansion and targeted national strategies to support biotech industrialization are driving rapid uptake of both instruments and outsourced services. The emphasis on scaling local capability has encouraged suppliers to localize manufacturing and support, and it has increased the attractiveness of reagent formulations and instrument configurations optimized for high-volume production. Taken together, these regional nuances argue for differentiated go-to-market approaches, localized validation efforts, and region-specific partnership strategies to ensure relevance and operational continuity.

Competitive behaviors, partnership models, and product strategies that distinguish market leaders and influence long-term positioning in gene synthesis ecosystems

Leading organizations within the gene synthesis ecosystem now compete on a combination of technological depth, ecosystem partnerships, and service reliability rather than on single product features alone. Companies that invest in modular platforms that integrate design, synthesis, and quality control gain traction among customers seeking turnkey workflows. Similarly, reagent suppliers that provide robust technical documentation and extended stability data reduce friction for regulated end users and earn preference in clinical and industrial settings.

Partnership patterns have shifted toward co-development arrangements with academic centers and commercial biotech firms, enabling faster validation cycles and broader application coverage. In addition, a subset of companies are pursuing service-first models, offering high-touch synthesis and design services that serve as entry points for longer-term instrument or reagent adoption. Strategic M&A and selective licensing agreements have also emerged as mechanisms to acquire niche capabilities or to expand addressable application spaces. Leadership in this sector increasingly requires balancing capital investments in automation and manufacturing with investments in regulatory, quality, and customer success capabilities to translate technical innovation into repeatable commercial outcomes.

Practical strategic moves for leaders to accelerate commercialization, strengthen resilience, and translate innovation into durable competitive advantage in gene synthesis

Industry leaders should prioritize a set of practical moves that align innovation efficiency with supply chain resilience and customer-centric commercialization. First, invest in modular automation and validated workflows that reduce handoffs and accelerate repeatable outcomes, because operational consistency underpins both research reproducibility and clinical-grade applications. Second, develop robust supplier diversification strategies and localized support to mitigate tariff and logistics risks while maintaining predictable access to enzymes, oligonucleotides, and specialty consumables.

Third, embed regulatory and biosecurity considerations into product design and customer onboarding to address emerging governance expectations and to lower barriers for clinical and diagnostic adoption. Fourth, cultivate partnerships that combine platform capabilities with application-specific expertise, thereby enabling co-developed solutions for antibody and vaccine production, molecular diagnostics, and synthetic biology. Fifth, prioritize customer success functions that translate technical advantages into measurable workflow improvements; investing in training, validated protocols, and dedicated technical support creates stickiness and accelerates adoption. Finally, consider flexible commercial models, including instrument-as-a-service and managed synthesis offerings, to broaden accessibility and lower entry barriers for high-value end users. Collectively, these actions will enable organizations to convert technology potential into sustainable competitive advantage.

Transparent research methodology describing primary and secondary inputs, validation processes, and analytical frameworks used to derive the gene synthesis insights

This analysis synthesizes primary and secondary inputs through a structured methodology emphasizing source triangulation, expert validation, and transparent analytical frameworks. Primary input included structured interviews and workshops with subject-matter experts spanning molecular biology, automation engineering, quality assurance, and commercial leadership. These engagements informed the interpretation of technological trade-offs, product integration patterns, and end-user purchasing behaviors.

Secondary input drew on peer-reviewed literature, regulatory guidance documents, manufacturer technical disclosures, and public filings where available, with attention to cross-referencing claims against independent validation sources. Analytical frameworks included capability mapping across instruments, reagents, and services; technology maturity assessments for chemical, enzymatic, and PCR-based synthesis routes; and scenario-based stress testing for supply chain disruptions such as tariff changes.

Data synthesis emphasized reproducibility and traceability: key assumptions and data sources were recorded, and conclusions were validated during follow-up expert reviews to minimize interpretive bias. Where uncertainty persisted, alternative hypotheses were documented to support transparent decision-making. This approach ensures that the insights presented are grounded in both practitioner experience and documented evidence, and that users can assess relevance to their specific operational or strategic questions.

Synthesis of strategic takeaways and a forward-looking perspective on how stakeholders can navigate disruption and capitalize on gene synthesis advancements

The cumulative picture points to a gene synthesis landscape in which integrated workflows, resilient supply chains, and application-driven validation will determine who converts scientific innovation into commercial impact. Technological plurality - with chemical, enzymatic, and PCR-based methods each offering distinct advantages - requires strategic clarity about where to focus engineering and go-to-market efforts. At the same time, regional disparities in infrastructure, regulatory posture, and procurement practices demand localized execution plans rather than one-size-fits-all approaches.

To succeed, organizations must balance short-term operational resilience with long-term investments in modular automation, validated reagents, and customer-facing services. Collaboration across the value chain-between instrument makers, reagent suppliers, service providers, and end users-will accelerate the translation of capability into outcomes such as faster vaccine development cycles, higher-throughput diagnostic pipelines, and scalable synthetic biology applications. Ultimately, the winners will be those who align technical excellence with pragmatic commercialization strategies and who purposefully design for compliance, scalability, and customer adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Synthesis Market, by Product

  • 8.1. Instruments
    • 8.1.1. Automated Cloning Instruments
    • 8.1.2. DNA Synthesizers
    • 8.1.3. Microarray Platforms
    • 8.1.4. Thermal Cyclers
  • 8.2. Reagents & Consumables
    • 8.2.1. Buffers & Other Consumables
    • 8.2.2. Enzymes & Kits
    • 8.2.3. Oligonucleotides
  • 8.3. Services
    • 8.3.1. Basic Gene Synthesis
    • 8.3.2. Gene Cloning
    • 8.3.3. Mutagenesis Services

9. Gene Synthesis Market, by Technology

  • 9.1. Chemical Synthesis
    • 9.1.1. H-Phosphonate Synthesis
    • 9.1.2. Phosphoramidite Synthesis
  • 9.2. Enzymatic Synthesis
    • 9.2.1. Gibson Assembly
    • 9.2.2. Golden Gate Assembly
    • 9.2.3. Ligase Chain Reaction
  • 9.3. PCR Based Synthesis

10. Gene Synthesis Market, by Application

  • 10.1. Antibody & Vaccine Production
  • 10.2. Industrial Biotechnology
  • 10.3. Molecular Diagnostics
  • 10.4. Stem Cell & Cell Line Engineering
  • 10.5. Synthetic Biology

11. Gene Synthesis Market, by End-User

  • 11.1. Academic & Research Institutes
  • 11.2. Clinical Diagnostics Laboratories
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Gene Synthesis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Synthesis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Synthesis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Synthesis Market

16. China Gene Synthesis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ansa Biotechnologies Inc.
  • 17.6. Arbor Biotechnologies, Inc.
  • 17.7. ATUM, Inc.
  • 17.8. Azenta Life Sciences, Inc.
  • 17.9. Bio Basic Inc.
  • 17.10. Bioneer Corporation
  • 17.11. DNA Script SA
  • 17.12. Eurofins Scientific SE
  • 17.13. Evonetix Ltd.
  • 17.14. GenScript Biotech Corporation
  • 17.15. Integrated DNA Technologies, Inc.
  • 17.16. Merck KGaA
  • 17.17. OriGene Technologies, Inc.
  • 17.18. ProteoGenix SAS
  • 17.19. Synbio Technologies Inc.
  • 17.20. Telesis Bio, Inc.
  • 17.21. Thermo Fisher Scientific Inc.
  • 17.22. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE SYNTHESIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE SYNTHESIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE SYNTHESIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE SYNTHESIS MARKET SIZE, BY AUTOMATED CLONING INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE SYNTHESIS MARKET SIZE, BY DNA SYNTHESIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE SYNTHESIS MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BUFFERS & OTHER CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMES & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE SYNTHESIS MARKET SIZE, BY OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE SYNTHESIS MARKET SIZE, BY BASIC GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GENE CLONING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MUTAGENESIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE SYNTHESIS MARKET SIZE, BY H-PHOSPHONATE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHOSPHORAMIDITE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GIBSON ASSEMBLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GOLDEN GATE ASSEMBLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE SYNTHESIS MARKET SIZE, BY LIGASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PCR BASED SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ANTIBODY & VACCINE PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE SYNTHESIS MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE SYNTHESIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE SYNTHESIS MARKET SIZE, BY STEM CELL & CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE SYNTHESIS MARKET SIZE, BY SYNTHETIC BIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. GCC GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 197. GCC GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. GCC GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. G7 GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 227. G7 GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. G7 GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. NATO GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 237. NATO GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. NATO GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES GENE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA GENE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA GENE SYNTHESIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA GENE SYNTHESIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA GENE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA GENE SYNTHESIS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA GENE SYNTHESIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA GENE SYNTHESIS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA GENE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA GENE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA GENE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)